Myeloid Therapeutics, a company developing in vivo cell therapies for cancer as well as a novel gene editing technology, has ...

Tariffs on pharmaceutical products that President Donald Trump has teased for weeks are one step closer to fruition after the ...

The centerpiece of Bristol Myers Squibb’s $13 billion MyoKardia acquisition failed a Phase 3 study meant to expand the ...

A panel of experts who decide the national immunization schedule will meet on Tuesday for the first time in 2025, providing ...

Duality Biologics, a Chinese antibody-drug conjugates startup, to go public on Hong Kong Stock Exchange with $194M IPO amid ...

Ab­b­Vie and San­doz have re­solved their patent dis­pute over Ab­b­Vie’s block­buster im­munol­o­gy drug Rin­voq. San­doz ...

After accumulating $86 billion in global sales, Amgen is still trying to keep Enbrel biosimilars off the market, Sandoz ...

In a development landscape as extensive as obesity, we think Pfizer could be better served by looking outside,' Stifel ...

The government is fighting in court for a plan to cut spending on overhead research costs for grantees. Primate centers fear ...

Commerce Secretary Howard Lutnick has indicated more specific timelines as to when pharma tariffs could surface, noting they ...

Verve Therapeutics is trying to swerve the gene editing industry downturn with new results on a potential one-time treatment to lower cholesterol. The experimental gene editing therapy cut bad ...

Under the 11-page 'roadmap' outlined Thursday, the goal is for animal testing to become 'the exception rather than the norm' ...